Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin randomized controlled study in type 2 diabetes mellitus with cardiac autonomic neuropathy
ChiCTR2500101113Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of henagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Heart rate variability and Cardiac autonomic function CARTs score. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500101113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101113.